TISLELIZUMAB

Information current as at: 1 September 2026

PBAC meeting date: July 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Tevimbra®
Form and strength:
  • Solution concentrate for I.V. infusion 100 mg in 10 ml
  • Solution concentrate for I.V. infusion 150 mg in 15 ml
Submission sponsor:
BEONE MEDICINES AUS PTY LTD
Condition/indication:
(therapeutic use)
  • Gastro-oesophageal cancer
Listing requested:
To request listing of tislelizumab for advanced or metastatic gastro-oesophageal cancer such that patients can be administered treatment with 150 mg once every two weeks (Q2W) and 300 mg once every four weeks (Q4W) as an alternative to the current dosing regimen of 200 mg once every 3 weeks (Q3W). The submission also seeks listing of a new 150 mg vial form of tislelizumab.
Funding program:
PBS Section 100 (Efficient Funding of Chemotherapy)
Request authority level:
Authority Required (STREAMLINED)
PBAC Submission type:
New PBS listing (Category 2)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2026 PBAC meeting
Opportunity for consumer comment:
Open 25/03/2026 and close 20/05/2026 (see PBS Website)
PBAC meeting:
Held on 08/07/2026
PBAC outcome published:
Deferred (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:

The PBAC recommendation cannot be made public until the TGA Outcome is known

Public Summary Document:
Not yet available
Case ID
1243
Page last updated
04 September 2026
Return to the Medicine Status Listing
v.9.19